AlphaQuest LLC Purchases 12,724 Shares of Keros Therapeutics, Inc. $KROS

AlphaQuest LLC increased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 96.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,958 shares of the company’s stock after purchasing an additional 12,724 shares during the period. AlphaQuest LLC’s holdings in Keros Therapeutics were worth $347,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Keros Therapeutics by 31.1% during the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock worth $26,151,000 after purchasing an additional 609,212 shares during the period. ADAR1 Capital Management LLC grew its stake in Keros Therapeutics by 6,294.5% in the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after acquiring an additional 1,463,215 shares during the period. Federated Hermes Inc. grew its stake in Keros Therapeutics by 882.3% in the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock valued at $12,474,000 after acquiring an additional 1,099,519 shares during the period. Goldman Sachs Group Inc. grew its stake in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after acquiring an additional 205,022 shares during the period. Finally, DRW Securities LLC acquired a new position in Keros Therapeutics in the first quarter valued at about $4,737,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The SEC filing for this sale provides additional information. 20.60% of the stock is owned by corporate insiders.

Keros Therapeutics Stock Performance

KROS opened at $15.03 on Friday. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The firm has a market capitalization of $457.96 million, a PE ratio of 48.49, a PEG ratio of 1.94 and a beta of 0.97. The business’s 50-day simple moving average is $15.44 and its 200 day simple moving average is $14.54.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. During the same quarter in the prior year, the company posted ($1.25) earnings per share. Keros Therapeutics’s revenue was up 49002.7% on a year-over-year basis. On average, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of research analyst reports. Wells Fargo & Company initiated coverage on Keros Therapeutics in a research note on Monday, October 20th. They issued an “overweight” rating and a $26.00 target price for the company. HC Wainwright reduced their price objective on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Keros Therapeutics in a research report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Hold” and an average price target of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.